Exited Investments
Ablation Frontiers, Inc.
Acquired by Medtronic in 2009
Ablation Frontiers has developed novel catheters and a unique energy source for the treatment of atrial fibrillation.
Acorda Therapeutics, Inc.
IPO in 2006, NASDAQ (GM): ACOR
Acorda developed therapies for spinal cord injury (SCI), multiple sclerosis (MS) and related neurological conditions. Marketed compound Zanaflex for spasticity.
Adenosine Therapeutics LLC
Acquired by Clinical Data in 2008
Adenosine Therapeutics is dedicated to development of novel pharmaceutical products that target adenosine receptor subtypes across a broad range of therapeutic applications.
CombinatoRx, Inc.
IPO in 2005, NASDAQ: CRXX
CombinatoRx combines existing medicines to attack diseases via multiple pathways. The company has an impressive pipeline of novel agents, including clinical programs in cancer and rheumatoid arthritis.
Cytos Biotechnology AG
IPO in 2002, SWX: CYTN
Cytos Biotechnology is dedicated to the discovery, development and commercialization of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic vaccines intended for use in the treatment and prevention of common chronic diseases which afflict millions of people worldwide.
ESBATech AG
Acquired by Alcon in 2009
ESBATech develops therapeutic single-chain fragment antibodies on the basis of its proprietary fully human antibody fragments for the treatment of various inflammatory diseases. The established know-how and expertise in antibody engineering is employed for the improvement and optimization of existing fragments for better stability and expression properties.
Eyetech Pharmaceuticals, Inc.
IPO in 2004, NASDAQ: EYET
A biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye, particularly the retina. Eyetech merged with OSI Pharma in 2005.
GlycArt Biotechnology AG
Acquired by Roche in 2005
Research, development and commercialization of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. GlycArt‘s glycosylation technology enhances the power of monoclonal antibodies.
Idenix Pharmaceuticals, Inc.
IPO in 2004, NASDAQ: IDIX
Idenix Pharmaceuticals is engaged in the discovery, development and commercialization of innovative treatments for human infectious diseases. Building on the company's expertise in medicinal chemistry and clinical development, Idenix is positioning itself to become a leader in the antiviral pharmaceutical market. Idenix has a robust pipeline focusing on agents that will significantly advance the treatment of hepatitis B, hepatitis C and HIV/AIDS by improving efficacy, safety and tolerability.
Infinity Pharmaceuticals, Inc.
Reverse merger into Discovery Partners in 2006, NASDAQ: INFI
Integrating unique approaches and capabilities in synthetic chemistry, chemical genetics, informatics, and biological screening, the company’s aim is to transform the drug discovery process and to increase its success rate.
IsoTis OrthoBiologics AG
IPO in 2000, SWX: ISON
IsoTis uses its expertise in cell-based technologies to develop therapeutic products for the treatment of wounds and skin diseases. IsoTis was acquired by Integra in 2007.
Kinetix Pharmaceuticals, Inc.
Acquired by Amgen in 2004
Kinetix is a biopharmaceutical company specialized in the discovery and development of small molecule drugs which regulate signal transduction by inhibiting specific protein kinases.
KuDOS Pharmaceuticals, Ltd.
Acquired by AstraZeneca in 2006
KuDOS Pharmaceuticals holds a leading position in the discovery and development of drugs based upon the science of DNA damage sensing, signalling and repair to address unmet medical needs in cancer treatment. KuDOS targets double stranded DNA repair pathways.
Miikana Therapeutics, Inc.
Acquired by EntreMed in 2006
Miikana Therapeutics is a clinically driven biopharmaceutical company discovering and developing targeted medicines for the treatment of cancer. Spin-out from the Amgen Research Institute.
Oscient Pharmaceuticals Corp.
IPO in 2005, NASDAQ: OSCI
Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The company is marketing its FDA-approved lead product FACTIVE® (gemifloxacin mesylate) tablets.
Silence Therapeutics plc
IPO in 2005, LON: SLN
Silence Therapeutics is the leading RNAi therapeutics company in Europe. The Company has developed novel, proprietary short interfering RNA (“siRNA”) molecules. These molecules provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells in the body, whilst increasing their bioavailability and circulation times.
Sirtris Pharmaceuticals, Inc.
IPO in 2007, NASDAQ: SIRT
Sirtris is developing small molecule drugs that target the sirtuins, a recently discovered family of seven enzymes associated with the aging process. It was acquired by GSK in 2008.
Speedel Holding, Ltd.
IPO in 2005, SWX: SPPN
Speedel is a biopharmaceutical company focusing on developing (lead to end phase II) innovative therapies for cardiovascular and metabolic diseases. Speedel is a leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases.
Swiss Pharma Contract AG
Acquired by Covance in 2009
Swiss Pharma Contract is an international clinical contract research organization offering a variety of clinical pharmacology services ranging from first testing in man to post-marketing studies.
Syrxx, Inc.
Acquired by Takeda in 2006
Syrrx is a structure-based drug discovery company working primarily on clinically validated drug targets in the areas of diabetes, cancer, and inflammation. Syrrx uses proprietary Nanovolume™ technologies to crystallize and determine the atomic structures of known drug targets, and then design best-in-class therapeutics.
Theravance, Inc.
IPO in 2004, NASDAQ: THRX
Theravance is focused on the discovery, development and commercialization of small-molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.
Torrey Pines Therapeutics, Inc.
Reverse merger into Axonyx in 2006, NASDAQ: TPTX
Formely NeuroGenetics, Torrey Pines is a biopharmaceutical company dedicated to translating genetic discoveries concerning complex disorders of the human brain into effective drugs against Alzheimer's disease and related neurodegenerative disorders.
Transform Pharmaceuticals, Inc.
Acquired by Johnson & Johnson in 2005
Transform Pharmaceuticals uses high-throughput automated technology to optimize and develop new and improved pharmaceutical products (formulation modifications) for its partners and its own proprietary product portfolio.
Visiogen, Inc.
Acquired by Abbott in 2009
Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating intraocular lens (IOL) for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses.
Xenoport, Inc.
IPO in 2005, NASDAQ: XNPT
XenoPort is focused on developing products which harness the body's intrinsic transport systems to improve the oral absorption, distribution, and pharmacokinetics of drugs. The company applies transporter genomics, assay technology, and proprietary chemistries, to engineer drug molecules for active transport. XenoPort applies its technology to off-patent drugs to provide new, patentable compounds with improved medicinal properties.